Zhang Y S, Yu H Y, Dong F, Li H Z
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100073, China.
Zhonghua Wai Ke Za Zhi. 2016 Jul 1;54(7):528-33. doi: 10.3760/cma.j.issn.0529-5815.2016.07.011.
To explore how clinical features of renal cell carcinoma (RCC) relate to cancer patients' prognosis and survival.
A total of 1 497 renal cell carcinoma patients received surgical treatments in Department of Urology, Peking Union Medical College were admitted between January 2002 and December 2012. Telephone interviews and complimentary medical records review were carried out to acquire follow-up data, including post-surgery adjuvant therapy, disease progression and survival.
There were 1 326 of all 1 497 RCC cases successfully followed up, including 899 male and 427 female cases. The median age was 54(18) years (M(QR)). There were 1 049 T1 cases (79.11%), 139 T2 cases (10.48%), 125 T3 cases (9.43%), and 13 T4 cases (0.98%). As for types of surgery, there were 584 (44.04%) nephron-sparing surgery cases, and 742 (55.96%) radical nephrectomy cases. As for pathological subtypes, it included 1 153 (86.95%) clear cell renal cell carcinoma cases, and 173 (13.05%) non-clear cell renal cell carcinoma cases. Median length of follow-up was 43.6 months. During follow-up, 147 patients developed RCC related progression, with a median progression free survival of 18.2 months.Sixty-four patients died from RCC related progression, with a median cancer specific survival (CSS) of 27.7 months. RESULTS of data analysis showed that CSS rates of 1-, 5-, 10-year of T1 stage post-surgical RCC were 99.61%, 97.24%, 92.08%, respectively; CSS rates of 1-, 5-, 10-year of T2 stage were 98.51%, 92.01%, 85.08%, respectively; and CSS rates of 1-, 5-, 10-year of T3-4 stage were 92.40%, 77.99%, 42.56%, respectively. Multivariable Cox regression analysis showed that signs of lung metastasis, signs of bone metastasis, tumor N stage, pathological subtype, microscopic sarcomatoid changing, and types of progression were major risk factors for RCC cancer specific survival (P<0.05).
Surgery is the primary choice of treatment in RCC. The survival is not same with different T stage. T stage affects the progression of renal cell carcinoma. N stage, lung and bone symptoms, pathological type, sarcomatoid changes and postoperative metastasis of renal cell carcinoma will affect the mortality of patients.
探讨肾细胞癌(RCC)的临床特征与癌症患者预后及生存的关系。
2002年1月至2012年12月期间,共有1497例在协和医科大学泌尿外科接受手术治疗的肾细胞癌患者入院。通过电话访谈和补充病历审查来获取随访数据,包括术后辅助治疗、疾病进展和生存情况。
1497例RCC病例中,有1326例成功随访,其中男性899例,女性427例。中位年龄为54(18)岁(M(QR))。T1期病例1049例(79.11%),T2期病例139例(10.48%),T3期病例125例(9.43%),T4期病例13例(0.98%)。手术类型方面,保留肾单位手术584例(44.04%),根治性肾切除术742例(55.96%)。病理亚型方面,透明细胞肾细胞癌1153例(86.95%),非透明细胞肾细胞癌173例(13.05%)。中位随访时间为43.6个月。随访期间,147例患者出现RCC相关进展,无进展生存期的中位数为18.2个月。64例患者死于RCC相关进展,癌症特异性生存(CSS)的中位数为27.7个月。数据分析结果显示,T1期术后RCC的1年、5年、10年CSS率分别为99.61%、97.24%、92.08%;T2期的1年、5年、10年CSS率分别为98.51%、92.01%、85.08%;T3 - 4期的1年、5年、10年CSS率分别为92.40%、77.99%、42.56%。多变量Cox回归分析显示,肺转移征象、骨转移征象、肿瘤N分期、病理亚型、显微镜下肉瘤样改变及进展类型是RCC癌症特异性生存的主要危险因素(P<0.05)。
手术是RCC的主要治疗选择。不同T分期的生存率不同。T分期影响肾细胞癌的进展。肾细胞癌的N分期、肺和骨症状、病理类型、肉瘤样改变及术后转移会影响患者的死亡率。